

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
Overall	Mild	36 (41.9%)	19 (22.6%)	22 (26.2%)
	Moderate	24 (27.9%)	42 (50.0%)	46 (54.8%)
	Severe	5 (5.8%)	16 (19.0%)	8 (9.5%)
	Total	65 (75.6%)	77 (91.7%)	76 (90.5%)
<hr/>				
CARDIAC DISORDERS	Mild	8 (9.3%)	8 (9.5%)	9 (10.7%)
	Moderate	2 (2.3%)	5 (6.0%)	5 (6.0%)
	Severe	2 (2.3%)	0	1 (1.2%)
	Total	12 (14.0%)	13 (15.5%)	15 (17.9%)
<hr/>				
ATRIAL FIBRILLATION	Mild	0	0	2 (2.4%)
	Moderate	1 (1.2%)	1 (1.2%)	0
	Severe	0	0	1 (1.2%)
	Total	1 (1.2%)	1 (1.2%)	3 (3.6%)
<hr/>				
ATRIAL FLUTTER	Mild	0	0	1 (1.2%)
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	1 (1.2%)
<hr/>				
ATRIAL HYPERTROPHY	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Total	1 (1.2%)	0	0
ATRIOVENTRICULAR BLOCK FIRST DEGREE	Mild	1 (1.2%)	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	0
ATRIOVENTRICULAR BLOCK SECOND DEGREE	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
BRADYCARDIA	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
BUNDLE BRANCH BLOCK LEFT	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
BUNDLE BRANCH BLOCK RIGHT	Mild	1 (1.2%)	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	0
<hr/>				
CARDIAC DISORDER	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
<hr/>				
CARDIAC FAILURE CONGESTIVE	Mild	0	0	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
MYOCARDIAL INFARCTION	Mild	1 (1.2%)	2 (2.4%)	3 (3.6%)
	Moderate	1 (1.2%)	0	1 (1.2%)
	Severe	2 (2.3%)	0	0
	Total	4 (4.7%)	2 (2.4%)	4 (4.8%)
<hr/>				
PALPITATIONS	Mild	0	0	0
	Moderate	0	2 (2.4%)	0
	Severe	0	0	0
	Total	0	2 (2.4%)	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
SINUS ARRHYTHMIA	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
SINUS BRADYCARDIA	Mild	1 (1.2%)	6 (7.1%)	4 (4.8%)
	Moderate	1 (1.2%)	1 (1.2%)	4 (4.8%)
	Severe	0	0	0
	Total	2 (2.3%)	7 (8.3%)	8 (9.5%)
SUPRAVENTRICULAR EXTRASYSTOLES	Mild	1 (1.2%)	1 (1.2%)	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	1 (1.2%)
SUPRAVENTRICULAR TACHYCARDIA	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
TACHYCARDIA	Mild	0	0	0
	Moderate	1 (1.2%)	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
VENTRICULAR EXTRASYSTOLES	Mild	0	1 (1.2%)	1 (1.2%)
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	2 (2.4%)	1 (1.2%)
<hr/>				
VENTRICULAR HYPERTROPHY	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
WOLFF-PARKINSON-WHITE SYNDROME	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	Mild	0	0	2 (2.4%)
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	2 (2.4%)
<hr/>				

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
VENTRICULAR SEPTAL DEFECT	Mild	0	0	2 (2.4%)
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	2 (2.4%)
EAR AND LABYRINTH DISORDERS	Mild	1 (1.2%)	1 (1.2%)	0
	Moderate	0	1 (1.2%)	1 (1.2%)
	Severe	0	0	0
	Total	1 (1.2%)	2 (2.4%)	1 (1.2%)
CERUMEN IMPACTION	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
EAR PAIN	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
VERTIGO	Mild	0	0	0
	Moderate	0	1 (1.2%)	1 (1.2%)
	Severe	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Total	0	1 (1.2%)	1 (1.2%)
EYE DISORDERS	Mild	1 (1.2%)	1 (1.2%)	0
	Moderate	1 (1.2%)	1 (1.2%)	1 (1.2%)
	Severe	0	0	0
	Total	2 (2.3%)	2 (2.4%)	1 (1.2%)
CONJUNCTIVAL HAEMORRHAGE	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
CONJUNCTIVITIS	Mild	0	0	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
EYE ALLERGY	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
EYE PRURITUS	Mild	1 (1.2%)	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
EYE SWELLING	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
VISION BLURRED	Mild	0	1 (1.2%)	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	1 (1.2%)	1 (1.2%)
<hr/>				
GASTROINTESTINAL DISORDERS	Mild	15 (17.4%)	10 (11.9%)	14 (16.7%)
	Moderate	2 (2.3%)	4 (4.8%)	4 (4.8%)
	Severe	0	0	2 (2.4%)
	Total	17 (19.8%)	14 (16.7%)	20 (23.8%)
<hr/>				
ABDOMINAL DISCOMFORT	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
ABDOMINAL PAIN	Mild	1 (1.2%)	2 (2.4%)	0
	Moderate	0	1 (1.2%)	1 (1.2%)
	Severe	0	0	0
	Total	1 (1.2%)	3 (3.6%)	1 (1.2%)
CONSTIPATION	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
DIARRHOEA	Mild	9 (10.5%)	4 (4.8%)	2 (2.4%)
	Moderate	0	0	2 (2.4%)
	Severe	0	0	0
	Total	9 (10.5%)	4 (4.8%)	4 (4.8%)
DYSPEPSIA	Mild	1 (1.2%)	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	0
DYSPHAGIA	Mild	0	0	0
	Moderate	0	1 (1.2%)	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				
FLATULENCE	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
GASTROINTESTINAL HAEMORRHAGE	Mild	0	0	0
	Moderate	0	0	0
	Severe	0	0	1 (1.2%)
	Total	0	0	1 (1.2%)
<hr/>				
GASTROOESOPHAGEAL REFLUX DISEASE	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
GLOSSITIS	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
HIATUS HERNIA	Mild	0	0	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
NAUSEA	Mild	2 (2.3%)	2 (2.4%)	5 (6.0%)
	Moderate	1 (1.2%)	1 (1.2%)	0
	Severe	0	0	1 (1.2%)
	Total	3 (3.5%)	3 (3.6%)	6 (7.1%)
RECTAL HAEMORRHAGE	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
SALIVARY HYPERSECRETION	Mild	0	0	4 (4.8%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	4 (4.8%)
STOMACH DISCOMFORT	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Total	0	0	1 (1.2%)
VOMITING	Mild	2 (2.3%)	2 (2.4%)	5 (6.0%)
	Moderate	1 (1.2%)	1 (1.2%)	2 (2.4%)
	Severe	0	0	0
	Total	3 (3.5%)	3 (3.6%)	7 (8.3%)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	Mild	16 (18.6%)	19 (22.6%)	19 (22.6%)
	Moderate	5 (5.8%)	21 (25.0%)	21 (25.0%)
	Severe	0	7 (8.3%)	0
	Total	21 (24.4%)	47 (56.0%)	40 (47.6%)
APPLICATION SITE BLEEDING	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
APPLICATION SITE DERMATITIS	Mild	5 (5.8%)	4 (4.8%)	2 (2.4%)
	Moderate	0	4 (4.8%)	5 (6.0%)
	Severe	0	1 (1.2%)	0
	Total	5 (5.8%)	9 (10.7%)	7 (8.3%)
APPLICATION SITE DESQUAMATION	Mild	0	1 (1.2%)	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				
APPLICATION SITE DISCHARGE	Mild	0	0	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)
<hr/>				
APPLICATION SITE DISCOLOURATION	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				
APPLICATION SITE ERYTHEMA	Mild	3 (3.5%)	4 (4.8%)	9 (10.7%)
	Moderate	0	6 (7.1%)	6 (7.1%)
	Severe	0	2 (2.4%)	0
	Total	3 (3.5%)	12 (14.3%)	15 (17.9%)
<hr/>				
APPLICATION SITE INDURATION	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
APPLICATION SITE IRRITATION	Mild	1 (1.2%)	3 (3.6%)	3 (3.6%)
	Moderate	2 (2.3%)	3 (3.6%)	6 (7.1%)
	Severe	0	3 (3.6%)	0
	Total	3 (3.5%)	9 (10.7%)	9 (10.7%)
APPLICATION SITE PAIN	Mild	0	0	1 (1.2%)
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	2 (2.4%)
APPLICATION SITE PERSPIRATION	Mild	0	0	1 (1.2%)
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	2 (2.4%)
APPLICATION SITE PRURITUS	Mild	5 (5.8%)	13 (15.5%)	10 (11.9%)
	Moderate	1 (1.2%)	8 (9.5%)	12 (14.3%)
	Severe	0	1 (1.2%)	0
	Total	6 (7.0%)	22 (26.2%)	22 (26.2%)
APPLICATION SITE REACTION	Mild	0	0	0
	Moderate	1 (1.2%)	0	1 (1.2%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Severe	0	0	0
	Total	1 (1.2%)	0	1 (1.2%)
APPLICATION SITE SWELLING	Mild	0	1 (1.2%)	1 (1.2%)
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	1 (1.2%)	2 (2.4%)
APPLICATION SITE URTICARIA	Mild	0	2 (2.4%)	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	2 (2.4%)	1 (1.2%)
APPLICATION SITE VESICLES	Mild	1 (1.2%)	3 (3.6%)	2 (2.4%)
	Moderate	0	1 (1.2%)	4 (4.8%)
	Severe	0	0	0
	Total	1 (1.2%)	4 (4.8%)	6 (7.1%)
APPLICATION SITE WARMTH	Mild	0	0	0
	Moderate	0	0	0
	Severe	0	1 (1.2%)	0
	Total	0	1 (1.2%)	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
ASTHENIA	Mild	0	0	0
	Moderate	1 (1.2%)	0	1 (1.2%)
	Severe	0	0	0
	Total	1 (1.2%)	0	1 (1.2%)
CHEST DISCOMFORT	Mild	0	0	2 (2.4%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	2 (2.4%)
CHEST PAIN	Mild	0	0	2 (2.4%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	2 (2.4%)
CHILLS	Mild	0	1 (1.2%)	1 (1.2%)
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	1 (1.2%)
FATIGUE	Mild	1 (1.2%)	3 (3.6%)	5 (6.0%)
	Moderate	0	2 (2.4%)	0
	Severe	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Total	1 (1.2%)	5 (6.0%)	5 (6.0%)
FEELING ABNORMAL	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
FEELING COLD	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
INFLAMMATION	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
MALAISE	Mild	0	1 (1.2%)	1 (1.2%)
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	1 (1.2%)	2 (2.4%)
OEDEMA	Mild	0	2 (2.4%)	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	2 (2.4%)	0
<hr/>				
OEDEMA PERIPHERAL	Mild	2 (2.3%)	0	1 (1.2%)
	Moderate	0	1 (1.2%)	1 (1.2%)
	Severe	0	0	0
	Total	2 (2.3%)	1 (1.2%)	2 (2.4%)
<hr/>				
PAIN	Mild	0	0	1 (1.2%)
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	1 (1.2%)
<hr/>				
PYREXIA	Mild	2 (2.3%)	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	2 (2.3%)	0	1 (1.2%)
<hr/>				
SECRETION DISCHARGE	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
SUDDEN DEATH	Mild	0	0	0
	Moderate	0	0	0
	Severe	0	1 (1.2%)	0
	Total	0	1 (1.2%)	0
SWELLING	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
ULCER	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
HEPATOBILIARY DISORDERS	Mild	0	0	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
HYPERBILIRUBINAEMIA	Mild	0	0	0
	Moderate	1 (1.2%)	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
IMMUNE SYSTEM DISORDERS	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				
HYPERSENSITIVITY	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				
INFECTIONS AND INFESTATIONS	Mild	11 (12.8%)	6 (7.1%)	10 (11.9%)
	Moderate	5 (5.8%)	2 (2.4%)	3 (3.6%)
	Severe	0	1 (1.2%)	0
	Total	16 (18.6%)	9 (10.7%)	13 (15.5%)
<hr/>				
BRONCHITIS	Mild	0	0	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
CELLULITIS	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
CERVICITIS	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
CYSTITIS	Mild	1 (1.2%)	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	1 (1.2%)
EAR INFECTION	Mild	2 (2.3%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	2 (2.3%)	0	0
GASTROENTERITIS VIRAL	Mild	0	0	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Total	1 (1.2%)	0	0
HORDEOLUM	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
INFLUENZA	Mild	1 (1.2%)	1 (1.2%)	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	1 (1.2%)
LOCALISED INFECTION	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
LOWER RESPIRATORY TRACT INFECTION	Mild	0	0	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)
NASOPHARYNGITIS	Mild	1 (1.2%)	3 (3.6%)	5 (6.0%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Moderate	1 (1.2%)	0	1 (1.2%)
	Severe	0	1 (1.2%)	0
	Total	2 (2.3%)	4 (4.8%)	6 (7.1%)
<hr/>				
PNEUMONIA	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				
RHINITIS	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
<hr/>				
UPPER RESPIRATORY TRACT INFECTION	Mild	4 (4.7%)	1 (1.2%)	2 (2.4%)
	Moderate	2 (2.3%)	0	1 (1.2%)
	Severe	0	0	0
	Total	6 (7.0%)	1 (1.2%)	3 (3.6%)
<hr/>				
URINARY TRACT INFECTION	Mild	2 (2.3%)	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	2 (2.3%)	0	1 (1.2%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
VAGINAL MYCOSIS	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
VIRAL INFECTION	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	Mild	3 (3.5%)	1 (1.2%)	1 (1.2%)
	Moderate	0	4 (4.8%)	3 (3.6%)
	Severe	1 (1.2%)	0	1 (1.2%)
	Total	4 (4.7%)	5 (6.0%)	5 (6.0%)
CONTUSION	Mild	1 (1.2%)	0	2 (2.4%)
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	2 (2.4%)
EXCORIATION	Mild	2 (2.3%)	0	0
	Moderate	0	1 (1.2%)	1 (1.2%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Severe	0	0	0
	Total	2 (2.3%)	1 (1.2%)	1 (1.2%)
<hr/>				
FACIAL BONES FRACTURE	Mild	0	0	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)
<hr/>				
FALL	Mild	1 (1.2%)	1 (1.2%)	1 (1.2%)
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	1 (1.2%)	2 (2.4%)	1 (1.2%)
<hr/>				
HIP FRACTURE	Mild	0	0	0
	Moderate	0	0	1 (1.2%)
	Severe	1 (1.2%)	0	1 (1.2%)
	Total	1 (1.2%)	0	2 (2.4%)
<hr/>				
JOINT DISLOCATION	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
SKIN LACERATION	Mild	1 (1.2%)	1 (1.2%)	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	1 (1.2%)	2 (2.4%)	0
WOUND	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
INVESTIGATIONS	Mild	8 (9.3%)	6 (7.1%)	4 (4.8%)
	Moderate	2 (2.3%)	0	2 (2.4%)
	Severe	0	0	0
	Total	10 (11.6%)	6 (7.1%)	6 (7.1%)
BIOPSY	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
BIOPSY PROSTATE	Mild	0	0	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Total	0	0	1 (1.2%)
BLOOD ALKALINE PHOSPHATASE INCREASED	Mild	0	0	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
BLOOD CHOLESTEROL INCREASED	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
BLOOD CREATINE PHOSPHOKINASE INCREASED	Mild	0	0	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
BLOOD GLUCOSE INCREASED	Mild	0	1 (1.2%)	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	1 (1.2%)
BLOOD URINE PRESENT	Mild	1 (1.2%)	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
BODY TEMPERATURE INCREASED	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				
CYSTOSCOPY	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	Mild	4 (4.7%)	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	4 (4.7%)	1 (1.2%)	0
<hr/>				
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED	Mild	1 (1.2%)	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Total	1 (1.2%)	1 (1.2%)	0
ELECTROCARDIOGRAM T WAVE INVERSION	Mild	2 (2.3%)	1 (1.2%)	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	2 (2.3%)	1 (1.2%)	1 (1.2%)
HEART RATE INCREASED	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
HEART RATE IRREGULAR	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
NASAL MUCOSA BIOPSY	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
WEIGHT DECREASED	Mild	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)
<hr/>				
METABOLISM AND NUTRITION DISORDERS	Mild	4 (4.7%)	0	1 (1.2%)
	Moderate	2 (2.3%)	1 (1.2%)	1 (1.2%)
	Severe	0	0	0
	Total	6 (7.0%)	1 (1.2%)	2 (2.4%)
<hr/>				
DECREASED APPETITE	Mild	0	0	0
	Moderate	1 (1.2%)	0	1 (1.2%)
	Severe	0	0	0
	Total	1 (1.2%)	0	1 (1.2%)
<hr/>				
DEHYDRATION	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
DIABETES MELLITUS	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
FOOD CRAVING	Mild	1 (1.2%)	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	0
HYPONATRAEMIA	Mild	0	0	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
INCREASED APPETITE	Mild	1 (1.2%)	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	1 (1.2%)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	Mild	3 (3.5%)	2 (2.4%)	3 (3.6%)
	Moderate	1 (1.2%)	4 (4.8%)	4 (4.8%)
	Severe	0	1 (1.2%)	0
	Total	4 (4.7%)	7 (8.3%)	7 (8.3%)
ARTHRALGIA	Mild	1 (1.2%)	0	0
	Moderate	0	2 (2.4%)	1 (1.2%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Severe	0	0	0
	Total	1 (1.2%)	2 (2.4%)	1 (1.2%)
ARTHRITIS	Mild	0	0	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)
BACK PAIN	Mild	1 (1.2%)	0	2 (2.4%)
	Moderate	0	1 (1.2%)	1 (1.2%)
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	3 (3.6%)
FLANK PAIN	Mild	0	0	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)
MUSCLE SPASMS	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	1 (1.2%)	0
	Total	0	1 (1.2%)	1 (1.2%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
MUSCULAR WEAKNESS	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
MYALGIA	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
PAIN IN EXTREMITY	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
SHOULDER PAIN	Mild	0	2 (2.4%)	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	2 (2.4%)	0
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	1 (1.2%)	1 (1.2%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Total	0	2 (2.4%)	1 (1.2%)
COLON CANCER	Mild	0	0	0
	Moderate	0	0	0
	Severe	0	1 (1.2%)	0
	Total	0	1 (1.2%)	0
MALIGNANT FIBROUS HISTIOCYTOMA	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
PROSTATE CANCER	Mild	0	0	0
	Moderate	0	0	0
	Severe	0	0	1 (1.2%)
	Total	0	0	1 (1.2%)
NERVOUS SYSTEM DISORDERS	Mild	6 (7.0%)	10 (11.9%)	13 (15.5%)
	Moderate	2 (2.3%)	7 (8.3%)	8 (9.5%)
	Severe	0	3 (3.6%)	4 (4.8%)
	Total	8 (9.3%)	20 (23.8%)	25 (29.8%)
AMNESIA	Mild	0	0	1 (1.2%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
<hr/>				
BALANCE DISORDER	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				
BURNING SENSATION	Mild	0	0	1 (1.2%)
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	2 (2.4%)
<hr/>				
COGNITIVE DISORDER	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
<hr/>				
COMPLEX PARTIAL SEIZURES	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
COORDINATION ABNORMAL	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
DIZZINESS	Mild	2 (2.3%)	5 (6.0%)	7 (8.3%)
	Moderate	0	3 (3.6%)	3 (3.6%)
	Severe	0	0	1 (1.2%)
	Total	2 (2.3%)	8 (9.5%)	11 (13.1%)
HEADACHE	Mild	3 (3.5%)	2 (2.4%)	4 (4.8%)
	Moderate	0	0	1 (1.2%)
	Severe	0	1 (1.2%)	0
	Total	3 (3.5%)	3 (3.6%)	5 (6.0%)
HEMIANOPIA HOMONYMOUS	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
HYPERSOMNIA	Mild	0	0	1 (1.2%)
	Moderate	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)
<hr/>				
LETHARGY	Mild	0	0	0
	Moderate	0	1 (1.2%)	1 (1.2%)
	Severe	0	0	0
	Total	0	1 (1.2%)	1 (1.2%)
<hr/>				
PARAESTHESIA	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
<hr/>				
PARAESTHESIA ORAL	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				
PARKINSON'S DISEASE	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
PAROSMIA	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
PARTIAL SEIZURES WITH SECONDARY GENERALISATION	Mild	0	0	0
	Moderate	0	0	0
	Severe	0	0	1 (1.2%)
	Total	0	0	1 (1.2%)
PSYCHOMOTOR HYPERACTIVITY	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
SOMNOLENCE	Mild	0	1 (1.2%)	1 (1.2%)
	Moderate	2 (2.3%)	2 (2.4%)	0
	Severe	0	0	0
	Total	2 (2.3%)	3 (3.6%)	1 (1.2%)
STUPOR	Mild	0	0	0
	Moderate	0	0	0
	Severe	0	1 (1.2%)	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Total	0	1 (1.2%)	0
SYNCOPE	Mild	0	1 (1.2%)	0
	Moderate	0	1 (1.2%)	2 (2.4%)
	Severe	0	2 (2.4%)	1 (1.2%)
	Total	0	4 (4.8%)	3 (3.6%)
SYNCOPE VASOVAGAL	Mild	0	0	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)
TRANSIENT ISCHAEMIC ATTACK	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	1 (1.2%)	1 (1.2%)
	Total	0	2 (2.4%)	1 (1.2%)
PSYCHIATRIC DISORDERS	Mild	7 (8.1%)	3 (3.6%)	4 (4.8%)
	Moderate	2 (2.3%)	6 (7.1%)	4 (4.8%)
	Severe	1 (1.2%)	1 (1.2%)	0
	Total	10 (11.6%)	10 (11.9%)	8 (9.5%)
AGITATION	Mild	2 (2.3%)	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Moderate	0	1 (1.2%)	1 (1.2%)
	Severe	0	1 (1.2%)	0
	Total	2 (2.3%)	2 (2.4%)	1 (1.2%)
<hr/>				
ANXIETY	Mild	0	3 (3.6%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	3 (3.6%)	0
<hr/>				
COMPLETED SUICIDE	Mild	0	0	0
	Moderate	0	0	0
	Severe	1 (1.2%)	0	0
	Total	1 (1.2%)	0	0
<hr/>				
CONFUSIONAL STATE	Mild	1 (1.2%)	0	1 (1.2%)
	Moderate	1 (1.2%)	3 (3.6%)	0
	Severe	0	0	0
	Total	2 (2.3%)	3 (3.6%)	1 (1.2%)
<hr/>				
DELIRIUM	Mild	0	0	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
DELUSION	Mild	1 (1.2%)	0	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	1 (1.2%)	0	1 (1.2%)
DEPRESSED MOOD	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
DISORIENTATION	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
HALLUCINATION	Mild	0	0	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)
HALLUCINATION, VISUAL	Mild	0	0	0
	Moderate	0	0	1 (1.2%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)
INSOMNIA	Mild	2 (2.3%)	0	2 (2.4%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	2 (2.3%)	0	2 (2.4%)
IRRITABILITY	Mild	0	1 (1.2%)	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	0
LIBIDO DECREASED	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
LISTLESS	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
NIGHTMARE	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
RESTLESSNESS	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
RENAL AND URINARY DISORDERS	Mild	3 (3.5%)	3 (3.6%)	1 (1.2%)
	Moderate	1 (1.2%)	0	2 (2.4%)
	Severe	0	0	0
	Total	4 (4.7%)	3 (3.6%)	3 (3.6%)
CALCULUS URETHRAL	Mild	0	0	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)
DYSURIA	Mild	1 (1.2%)	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Total	1 (1.2%)	1 (1.2%)	0
INCONTINENCE	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
MICTURITION URGENCY	Mild	1 (1.2%)	1 (1.2%)	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	1 (1.2%)
NEPHROLITHIASIS	Mild	0	0	0
	Moderate	1 (1.2%)	0	1 (1.2%)
	Severe	0	0	0
	Total	1 (1.2%)	0	1 (1.2%)
POLLAKIURIA	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	Mild	1 (1.2%)	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Moderate	0	0	1 (1.2%)
	Severe	1 (1.2%)	0	0
	Total	2 (2.3%)	0	1 (1.2%)
<hr/>				
BENIGN PROSTATIC HYPERPLASIA	Mild	0	0	0
	Moderate	0	0	1 (1.2%)
	Severe	1 (1.2%)	0	0
	Total	1 (1.2%)	0	1 (1.2%)
<hr/>				
PELVIC PAIN	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	Mild	7 (8.1%)	6 (7.1%)	8 (9.5%)
	Moderate	1 (1.2%)	3 (3.6%)	2 (2.4%)
	Severe	0	0	0
	Total	8 (9.3%)	9 (10.7%)	10 (11.9%)
<hr/>				
ALLERGIC GRANULOMATOUS ANGIITIS	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
COUGH	Mild	1 (1.2%)	3 (3.6%)	3 (3.6%)
	Moderate	0	2 (2.4%)	2 (2.4%)
	Severe	0	0	0
	Total	1 (1.2%)	5 (6.0%)	5 (6.0%)
DYSPHONIA	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
DYSPNOEA	Mild	0	0	1 (1.2%)
	Moderate	1 (1.2%)	1 (1.2%)	0
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	1 (1.2%)
EMPHYSEMA	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
EPISTAXIS	Mild	0	1 (1.2%)	2 (2.4%)
	Moderate	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Severe	0	0	0
	Total	0	1 (1.2%)	2 (2.4%)
<hr/>				
HAEMOPTYSIS	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
NASAL CONGESTION	Mild	3 (3.5%)	1 (1.2%)	3 (3.6%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	3 (3.5%)	1 (1.2%)	3 (3.6%)
<hr/>				
PHARYNGEAL ERYTHEMA	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
<hr/>				
PHARYNGOLARYNGEAL PAIN	Mild	0	1 (1.2%)	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	1 (1.2%)
<hr/>				

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
POSTNASAL DRIP	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
PRODUCTIVE COUGH	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
RALES	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
RESPIRATORY TRACT CONGESTION	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
RHINORRHOEA	Mild	0	1 (1.2%)	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Total	0	1 (1.2%)	1 (1.2%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	Mild	12 (14.0%)	12 (14.3%)	24 (28.6%)
	Moderate	8 (9.3%)	23 (27.4%)	15 (17.9%)
	Severe	0	4 (4.8%)	1 (1.2%)
	Total	20 (23.3%)	39 (46.4%)	40 (47.6%)
ACTINIC KERATOSIS	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
ALOPECIA	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
BLISTER	Mild	0	1 (1.2%)	1 (1.2%)
	Moderate	0	3 (3.6%)	0
	Severe	0	1 (1.2%)	0
	Total	0	5 (6.0%)	1 (1.2%)
COLD SWEAT	Mild	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
DERMATITIS CONTACT	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				
DRUG ERUPTION	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
<hr/>				
ERYTHEMA	Mild	4 (4.7%)	6 (7.1%)	10 (11.9%)
	Moderate	4 (4.7%)	8 (9.5%)	4 (4.8%)
	Severe	0	0	0
	Total	8 (9.3%)	14 (16.7%)	14 (16.7%)
<hr/>				
HYPERHIDROSIS	Mild	2 (2.3%)	1 (1.2%)	8 (9.5%)
	Moderate	0	3 (3.6%)	0
	Severe	0	0	0
	Total	2 (2.3%)	4 (4.8%)	8 (9.5%)

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
PRURITUS	Mild	7 (8.1%)	9 (10.7%)	17 (20.2%)
	Moderate	1 (1.2%)	11 (13.1%)	9 (10.7%)
	Severe	0	1 (1.2%)	0
	Total	8 (9.3%)	21 (25.0%)	26 (31.0%)
PRURITUS GENERALISED	Mild	0	0	1 (1.2%)
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	1 (1.2%)
RASH	Mild	2 (2.3%)	9 (10.7%)	5 (6.0%)
	Moderate	3 (3.5%)	3 (3.6%)	3 (3.6%)
	Severe	0	1 (1.2%)	1 (1.2%)
	Total	5 (5.8%)	13 (15.5%)	9 (10.7%)
RASH ERYTHEMATOUS	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
RASH MACULO-PAPULAR	Mild	0	0	1 (1.2%)
	Moderate	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)
<hr/>				
RASH PRURITIC	Mild	0	0	1 (1.2%)
	Moderate	0	1 (1.2%)	1 (1.2%)
	Severe	0	0	0
	Total	0	1 (1.2%)	2 (2.4%)
<hr/>				
SKIN EXFOLIATION	Mild	0	0	0
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				
SKIN IRRITATION	Mild	2 (2.3%)	2 (2.4%)	3 (3.6%)
	Moderate	1 (1.2%)	3 (3.6%)	2 (2.4%)
	Severe	0	1 (1.2%)	0
	Total	3 (3.5%)	6 (7.1%)	5 (6.0%)
<hr/>				
SKIN ODOUR ABNORMAL	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
<hr/>				

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
SKIN ULCER	Mild	0	0	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
URTICARIA	Mild	0	0	1 (1.2%)
	Moderate	0	1 (1.2%)	0
	Severe	0	0	0
	Total	0	1 (1.2%)	1 (1.2%)
SOCIAL CIRCUMSTANCES	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
ALCOHOL USE	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
SURGICAL AND MEDICAL PROCEDURES	Mild	1 (1.2%)	1 (1.2%)	2 (2.4%)
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Total	2 (2.3%)	1 (1.2%)	2 (2.4%)
ACROCHORDON EXCISION	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
CATARACT OPERATION	Mild	0	1 (1.2%)	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	0
EYE LASER SURGERY	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0
SKIN LESION EXCISION	Mild	0	0	1 (1.2%)
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	0	1 (1.2%)
VASCULAR DISORDERS	Mild	1 (1.2%)	3 (3.6%)	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
	Moderate	2 (2.3%)	0	1 (1.2%)
	Severe	0	0	0
	Total	3 (3.5%)	3 (3.6%)	1 (1.2%)
<hr/>				
HOT FLUSH	Mild	0	1 (1.2%)	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	0	1 (1.2%)	0
<hr/>				
HYPERTENSION	Mild	0	1 (1.2%)	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	1 (1.2%)	1 (1.2%)	0
<hr/>				
HYPOTENSION	Mild	1 (1.2%)	1 (1.2%)	0
	Moderate	1 (1.2%)	0	0
	Severe	0	0	0
	Total	2 (2.3%)	1 (1.2%)	0
<hr/>				
ORTHOSTATIC HYPOTENSION	Mild	1 (1.2%)	0	0
	Moderate	0	0	0
	Severe	0	0	0
	Total	1 (1.2%)	0	0

Treatment-Emergent Adverse Events by Maximum Severity
Safety Analysis Set
Copyright @ mycsg.in

System Organ Class Preferred Term	Maximum Severity	Placebo (N=86) n (%)	Low Dose (N=84) n (%)	High Dose (N=84) n (%)
WOUND HAEMORRHAGE	Mild	0	0	0
	Moderate	0	0	1 (1.2%)
	Severe	0	0	0
	Total	0	0	1 (1.2%)